180 results about "Intestinal cell" patented technology

The invention relates to compositions and methods for the administration of therapeutic and/or diagnostic agents such as polypeptides to a mammal, and in particular, compositions suitable for oral administration. The invention provides polymeric particles, and in particular, nano/microparticles such as, but not limited to, microspheres and nanospheres, as well as methods of synthesizing them. The invention also provides methods of increasing the serum concentration of a therapeutic agent such as a polypeptide by orally administering polymeric particles comprising the therapeutic agent. The compositions of the invention allow the absorption of polypeptides through intestinal mucosa and intestinal cells and into the bloodstream of a mammal. The invention further provides a method of treating type II diabetes through the oral administration of compositions comprising insulin and also provides a related glucose-responsive insulin delivery system.

The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension.

The invention belongs to the field of pharmaceutical agents, relates to a polymer micelle lyophilized agent encapsulating an insoluble antitumor drug as well as a preparation method and an application thereof. The polymer micelle lyophilized agent is prepared by carrying out molecular self-assembly on a methoxy poly(ethylene glycol) 2000-polyester block copolymer to form micelles, and then encapsulating the insoluble antitumor drug in a hydrophobic core formed by the polyester. The lyophilized agent has high encapsulation rate, high drug loading and small particle size, can significantly improve the water solubility of the insoluble drug and result in passive targeting of more antitumor drugs to concentrate in the tumor tissues, thus improving an anti-tumor treatment effect and reducing the toxic and side effects of drugs, and can be used to prepare the drugs used for the treatment of lung cancer, intestinal cancer, mammary cancer, ovarian cancer, etc. The lyophilized agent can also be quickly dissolved and dispersed to form a transparent micellar solution after water for injection, normal saline solution and the like are added, and is used for the preparation of the drugs for treating primary intestinal cell carcinoma.

Methods are provided for long term culture of mammalian intestinal cells. Cultures are initiated with fragments of mammalian intestinal tissue, which are then maintained embedded in a gel substrate that provides an air-liquid interface. Intestinal epithelium in cultures of the invention can be continuously grown for extended periods of time. Mammalian intestinal cells cultured by the methods of the invention recapitulate features of intestinal growth in vivo.

A Lactobacillus plantarum BB9 capable of adhering to gastrointestinal tract and cholesterol removal is isolated from fruits and exhibits high BSH activity. In-vitro tests demonstrate that Lactobacillus plantarum BB9 has good acid and bile tolerance, and strong ability to adhere to intestinal cells. In-vivo tests show that hamsters fed high cholesterol diets added with BB9 strain have cholesterol and triglycerides in blood and liver effectively reduced, and their HDL-c/LDL-c ratios in blood are significantly higher than those of hamsters fed Lactobacillus acidophilus ATCC 43121 strain. It is hoped that the excellent acid and bile tolerance and intestinal adherence of the lactobacillus strain provided herein could produce cholesterol-lowering effect in humans.

Disclosed are materials and methods relevant to taste transduction. Also disclosed are human gastrointestinal cells that comprise or are capable expressing endogenous taste signaling proteins. Also disclosed are human gastrointestinal cells that comprise or are capable of expressing endogenous taste signaling proteins as well as hormones, neurotransmitters or soluble mediators of the gastrointestinal tract that are involved in or affect metabolism, digestion and appetite. Also disclosed are the uses of these human cells or their membranes to study how compounds affect taste transduction and/or metabolism, digestion and appetite, including effects on satiety, emesis and diabetes.

The present invention provides the use of ATP for the manufacture of a medicine for exerting a pharmacological effect when administered to a mammal, preferably a human, selected from the group consisting of: 1°. modulating inflammation by inhibiting the inflammatory response to a strong external insult such as endotoxin (LPS) and/or phytohaemagglutinin; 2°. exerting said inhibitory effect on inflammatory response to an external stimulus even under conditions of oxidative stress, 3°. exerting a local immuno-modulating and anti-inflammatory effect in the intestine, thus preventing intestinal damage induced by a non-steroid anti-inflammatory drug (NSAIDs), 4°. exerting an immuno-modulating and anti-inflammatory effect in human intestinal cells in vitro, 5°. alleviating pulmonary symptoms, such as shortness of breath and dyspnoea, in patients suffering from an obstructive pulmonary disease, and 6°. exerting favorable clinical effects with respect to certain mental and neurological disorders and aberrant conditions. The medicine is preferably manufactured in lyophilized form.

The present invention relates to the use of a supernatant of lactic acid bacteria or of Bifidobacteria capable of preventing colonization of intestinal cells by Giardia intestinalis, for the preparation of an ingestable carrier for the treatment and/or prophylaxis of disorders associated with the colonization of the gut by Giardia intestinalis. The present invention also pertains to specific strains of Bifidobacterium having the above traits and to the ingestable carrier, such as a food or pharmaceutical composition containing such supernatant or the microorganisms.

The invention provides lactobacillus plantarum resistant to enteritis salmonella infection and the application thereof and belongs to the technical field of microorganisms.The lactobacillus plantarum is preserved in the China General Microbiological Culture Collection Center (CGMCC) on Sep, 24th, 2015 with the preservation number of CGMCC No.11446.The lactobacillus plantarum CGMCC No.11446 has high acid and cholate resistance, and has a remarkable inhibition effect on growth of enteritis salmonella.Adhesion of enteritis salmonella to enterocyte HT-29 is strongly inhibited, and enteritis salmonella infection is prevented or relieved.The lactobacillus plantarum CGMCC No.11446 can be used for preparing pharmaceutical compositions for preventing or relieving enteritis salmonella, food containing activity lactobacillus and fermented food, and has broad application prospects.

The invention discloses an insulin carrying microsphere. A polyesteramide material of which the side chain contains a carboxyl and a hydrophobic isobutyl group at the same time serves as a carrier, wherein the carboxyl endows entericsolubility to the insulin carrying microsphere. Under a strong-acidity environment of gastric juice, because of deprotonation of the carboxyl, the polyesteramide material is not dissolved, the microsphere has certain contractile effect, and then a protein medicament is protected. Under a neutral condition of a small intestine, because of ionization of the carboxyl, the polyesteramide material is gradually dissolved, the microsphere is corroded, and then the wrapped medicament is released. On the other hand, the hydrophobic isobutyl has the effect of regulatingthe pH sensitivity of the material, the hydrophobicity of the insulin carrying microsphere is improved, and the effect with an intestinal cell membrane is enhanced. Therefore, the insulin carrying microsphere has high pH sensitivity, and the releasing and absorption of the insulin in an intestinal tract can be realized.

The present invention relates to methods of reducing the risk of occurrence of, and/or treating, necrotizing enterocolitis (“NEC”) or inflammatory bowel disease (“IBD”) comprising administering, to a subject in need of such treatment, an effective amount of a gap junction enhancing agent (“GJEA”), for example a peptide (“GJP”) or peptide analog (“GJPA”). It is based, at least in part, on the discovery that greater functionality of gap junctions between enterocytes increases their rate of migration and reduces the severity of intestinal inflammation.

The invention relates to an oridonin cubic liquid crystal nanoparticle and a preparation method thereof. The oridonin cubic liquid crystal nanoparticle is prepared from the following raw materials in percentage by weight: 0.1 to 0.5 percent of oridonin, 7 to 64 percent of amphiphilic lipid material, 6 to 29 percent of solvent, 1 to 8 percent of stabilizer, and 25 to 65 percent of water, wherein the amphiphilic lipid material is glycerol mono-oleate or phytould likeriol; the mass ratio of a liquid crystal material to the stabilizer is 1 to (0.01 to 0.30). The oridonin cubic liquid crystal nanoparticle provided by the invention is smaller in particle size, good in uniformity, and beneficial to endocytosis and transfer of enterocyte; by utilizing a unique structure of cubic liquid crystal, a dissolution barrier and a permeation barrier of the oridonin during an oral absorption process are effectively overcome, the oral relative bioavailability of the oridonin is remarkably improved, and meanwhile, the oridonin can be slowly released.

Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.

An object of the present invention is to provide a method of producing intestinal cells by use of pluripotent stem cells as a starting material. According to the present invention, provided is a method of producing intestinal cells, comprising the steps of: (A) inducing differentiation of pluripotent stem cells into definitive endoderm cells; and (B) culturing the definitive endoderm cells in the presence of (2′Z,3′E)-6-bromoindirubin-3′-oxime (BIO) and N-[(3,5-difluorophenyl)acetyl]-L-Ala-2-phenyl-L-Gly-tert-butyl-OH (DAPT) to thereby induce differentiation of the definitive endoderm cells into intestinal cells.

A method of making a live cell construct is carried out by: (a) providing a non-cellular support having a top surface and a bottom surface, (b) contacting live undifferentiated cells to the non-cellular support, and then (c) propagating a gastrointestinal epithelial cell monolayer on said top surface. In some embodiments, the live cells in the monolayer include: (i) undifferentiated cells (e.g., stem or progenitor cells); and (ii) optionally, but in some embodiments preferably, differentiated cells (e.g., enterocytes, Paneth cells, enteroendocrine cells, tuft cells, microcells, intra-epithelial lymphocytes, and/or goblet cells). Constructs formed by such methods and methods of using the same (e.g., in high through-put screening) are also described.

The present invention provides a pH sensitive nanoparticulate delivery system for the administration of peptide hormones and drugs. In particular it provides a pH sensitive nanoparticulate for oral insulin administration. The nanoparticles developed by this process are fatty acid nanoparticles and a polymer is used as a stabilizer and also to incorporate pH sensitivity so that these particles shrink in the gastric acidic pH thereby protecting the incorporated insulin. These particles being also hydrophobic in nature and by virtue of their small size get absorbed through the intestinal cell wall and Peyer's patches. These nanoparticles are novel and unique in the sense that polymer content is only 0.03-0.06 g/g product and the polymer is hydrophilic in nature.

A method for isolating viable, biologically substantially pure exfoliated fecal colonocytes at normal ambient temperature is described. Immunocoprocytes and inflammatory cells indicative of certain gastrointestinal conditions and a noninvasive method for detecting colorectal cancer are set forth. Composition of transport and suspension media for isolation of colonocytes are detailed.

The invention discloses a suspension culture method for intestinal cells of stomachless lukewarm water fish. According to the invention, collected intestinal cell suspension is mixed together for refrigeration and centrifugation for 10 min at 1500 Xg; collected cell deposition is suspended with a solution -3 anew and subjected to oscillation incubation at a temperature of 25 DEG C for 15 min, andsuspension of intestinal cells is filtered with a blood nylon filter having a bore diameter of 100 -mu m and subjected to refrigeration and centrifugation for 10 min at 1500 Xg; obtained cell deposition is suspended in a solution -3 anew for subsequent usage in tests; the integrity of cell membranes is detected by using the method of 0.5% typan blue exclusion; cell suspension and dyes are isopyknicly mixed and added on a counting panel drop by drop, a coverslip is covered, and after the counting panel is stood for one minute, the number of dead cells, the total number of cells and the cell viability are calculated; the cell suspension is subjected to refrigeration and centrifugation for 10 min at 1500 Xg, and the activity of a liquid supernatant and cell deposition LDH is determined respectively; the cell suspension is lightly and evenly mixed, a desired amount of the cell suspension is taken for oscillation incubation at a temperature of 26 DEG C, a rotate speed is 70 revolution/min,and total culture time is 240 minutes. The invention brings forward the suspension culture method for intestinal cells of stomachless lukewarm water fish for the first time.